Thomas F. Isett
Chief Executive Officer & Chairman of the Board
Prior to becoming CEO for iBio in March 2020, Mr. Isett played an integral part in reshaping the Company’s strategy and operations in his role as Board Member and Strategic Advisor since April 2019. He was able to contribute his deep management and strategic insights via the consulting firm he founded in 2015, i.e. Advising, LLC, which supported Fortune 500s, institutional investors, biotechs and non-profits alike with M&A, turnarounds, and more.
Previously, he ran business units for GE, Lonza, and BD, ranging in size from start-up to a half billion in revenues. Notably, he founded BD Advanced Bioprocessing (which sold to ThermoFisher in 2018 for $477M), and Commence Bio, Inc. a cellular immunotherapy company. Mr. Isett received his B.Sc. degree with Honors in Biological Sciences from Drexel University.
Martin B. Brenner
Chief Scientific Officer
Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world’s leading pharmaceutical companies, including AstraZeneca, Eli Lilly and Company, Pfizer Inc., and Merck Research Laboratories. Most recently, Dr. Brenner served as the CSO at Pfenex Inc., which, using its patented Pfēnex Expression Technology® platform, created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. Pfenex was acquired by Ligand Pharmaceuticals Incorporated for approximately $516 million in October 2020.
Previously, Dr. Brenner served as the CSO at Recursion Pharmaceuticals, Inc., a company focused on accelerating drug discovery for rare diseases and diseases with high unmet medical need. Prior to his time at Recursion, he was Vice President and Head of Research & Early Development at Stoke Therapeutics, Inc., a biotechnology company using antisense oligonucleotides to increase gene expression for the treatment of rare diseases. Prior to Stoke, he was Executive Director at Merck, where he built a biotech unit from scratch, focusing his team’s research on diabetes and nonalcoholic steatohepatitis (NASH). Earlier in his career, Dr. Brenner was the Senior Director and Head of cardiovascular, renal, and metabolism (CVRM) biosciences at AstraZeneca. In addition, Dr. Brenner was an Associate Research Fellow at Pfizer where he led the islet biology and in vivo pharmacology in the CVMED Target Exploration Unit before assuming the role of Head of the Insulin Resistance Group.
Chief Human Resources Officer
Ms. Middlebrook has more than 25 years of global human resources experience in life sciences. Before joining iBio in January 2021, she was SVP-Human Resources -The Americas for Lupin Limited, a multinational branded and generics pharmaceutical company. Previously, Ms. Middlebrook held various HR leadership positions during her 15 years at Lonza. During her career, Ms. Middlebrook has been a strategic business partner developing HR programs that support and enable organizational growth. She holds a B.S. in Industrial Relations from LeMoyne College and a M.S. in Applied Behavioral Science from Johns Hopkins University.
Robert M. Lutz
Chief Financial & Business Officer
Mr. Lutz brings more than 25 years of experience to the Company, joining most recently from Strongbridge Biopharma plc (“Strongbridge”), a Nasdaq-listed, commercial-stage biopharmaceutical company focused on rare diseases. He served as CFO since August 2019, and prior to that, as Chief Business Officer since October 2014. During his tenure, he led the search, evaluation, contracting, and financing of multiple assets which proved to be critical growth drivers for Strongbridge.
Before joining Strongbridge, Mr. Lutz spent more than a decade at Shire Pharmaceuticals (“Shire”) in leadership positions with global responsibilities, including identifying opportunities for acquisition, licensing, partnership and development for Shire’s largest business unit (Neuroscience) and the financial management of approximately $5 billion in revenue for its Specialty Pharmaceuticals division. Prior to joining Shire, Mr. Lutz served in a variety of financial, strategic and executive positions after having started his career at Goldman Sachs & Company. He holds an MBA from the Kellogg School of Management and a BA in Economics and Computer Science from Amherst College.
Mr. Banjak joins iBio with over 15 years’ experience in the biotechnology and contract research industries. He previously served as the first general counsel of both Istari Oncology and Dova Pharmaceuticals, leading the legal and compliance functions within both organizations. While at Dova, Mr. Banjak advised the company through a number of clinical and corporate milestones, including FDA and EMA approvals, a secondary public offering and the acquisition of Dova by Swedish Orphan Biovitrum AB. Prior to that, Mr. Banjak negotiated strategic contracts, advised on Foreign Corrupt Practices Act (FCPA) and Anti-Bribery matters, and labor issues at PRA Health Sciences. His industry experience spans rare disease biotechnology companies, global contract research organizations, and medical device companies. Prior to entering the biotechnology and contract research industries, Mr. Banjak served as an active duty officer in the U.S. Air Force in a variety of legal roles.
Mr. Banjak was admitted to the Colorado state bar. He earned his JD from the University of Denver School of Law and a BA in Psychology from Franklin and Marshall College.